AGM의 결과
Hikma 제약 PLC
2024년 연차총회 결과
런던, 25 April 2024 Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75) (the '기업 정보'또는'히크마')는 연례 총회('AGM') was held at Sofitel London St James, 6 Waterloo Place, London SW1Y 4AN earlier today (25 April 2024) and commenced at 11.00 am. All the proposed resolutions were duly passed by shareholders by way of a poll. Resolutions 1 to 17 (inclusive) were passed as ordinary resolutions and Resolutions 18 to 21 (inclusive) were passed as special resolutions. Resolutions 22 to 25 (inclusive) were passed as ordinary resolutions on which only Independent Shareholders (that is, excluding members of the Darhold Concert Party, in accordance with the City Code on Takeovers and Mergers) were entitled to vote.
Copies of the resolutions dealing with special business passed at the AGM have been submitted to the FCA's Electronic Submission System and will be available from the National Storage Mechanism. Capitalised terms used but not otherwise defined in this announcement shall have the meanings given to them in the Notice of Meeting dated 22 March 2024.
The total number of votes cast on the poll for each resolution (the full text of the resolutions is detailed in the Notice of Meeting dated 22 March 2024) is set out below. The number of Ordinary Shares in issue at the close of business on 23 April 2024 was 234,718,492. At that time there were 12,833,233 Ordinary Shares held in treasury, which are not counted in the voting capital of the Company which, therefore, was 221,885,259.
분해능 | 투표 | % of Eligible Votes | 반대 투표 | % of Eligible Votes | 총 투표수 | ISC의 %로 부여된 총 투표 수1 | 보류2 |
1. 2023년 보고서 및 결산을 받아보시려면 | 181,198,032 | 99.77% | 420,652 | 0.23% | 181,618,684 | 81.85% | 2,002,379 |
2. 주당 47센트의 최종 배당금 승인 | 183,619,000 | 100.00% | - | 0.00% | 183,619,000 | 82.75% | 2,063 |
3. PricewaterhouseCoopers LLP를 감사로 재임명하기 위해 | 182,047,455 | 99.14% | 1,571,545 | 0.86% | 183,619,000 | 82.75% | 2,063 |
4. 감사 위원회가 감사의 보수를 결정하도록 권한을 부여하기 위해 | 183,350,922 | 99.85% | 268,755 | 0.15% | 183,619,677 | 82.75% | 1,386 |
5. To elect Riad Mishlawi as a Director | 182,679,147 | 99.49% | 931,142 | 0.51% | 183,610,289 | 82.75% | 10,774 |
6. Said Darwazah를 이사로 재선임 | 175,159,173 | 95.46% | 8,330,791 | 4.54% | 183,489,964 | 82.70% | 131,099 |
7. Mazen Darwazah를 이사로 재선출 | 173,570,357 | 94.59% | 9,919,072 | 5.41% | 183,489,429 | 82.70% | 131,634 |
8. To re-elect Victoria Hull as a Director | 171,362,071 | 93.33% | 12,252,259 | 6.67% | 183,614,330 | 82.75% | 6,733 |
9. Ali Al-Husry를 이사로 재선출 | 181,637,139 | 98.99% | 1,851,670 | 1.01% | 183,488,809 | 82.70% | 132,254 |
10. John Castellani를 이사로 재선출 | 182,829,533 | 99.57% | 783,105 | 0.43% | 183,612,638 | 82.75% | 8,425 |
11. Nina Henderson을 이사로 재선출하기 위해 | 182,724,512 | 99.52% | 889,994 | 0.48% | 183,614,506 | 82.75% | 6,557 |
12. Cynthia Flowers를 이사로 재선출하기 위해 | 182,948,600 | 99.64% | 665,730 | 0.36% | 183,614,330 | 82.75% | 6,733 |
13. 더글라스 허트를 감독으로 재선출하기 위해 | 182,827,276 | 99.57% | 785,362 | 0.43% | 183,612,638 | 82.75% | 8,425 |
14. To re-elect Laura Balan as a Director | 183,048,421 | 99.69% | 565,909 | 0.31% | 183,614,330 | 82.75% | 6,733 |
15. To re-elect Dr Deneen Vojta as a Director | 183,188,326 | 99.77% | 426,004 | 0.23% | 183,614,330 | 82.75% | 6,733 |
16. 보수에 관한 연례 보고서를 받고 승인하기 위해 | 167,893,145 | 91.44% | 15,724,640 | 8.56% | 183,617,785 | 82.75% | 3,278 |
17. 이사에게 주식을 할당하고 주식을 청약할 수 있는 권한을 부여하기 위해 | 177,588,670 | 96.74% | 5,992,661 | 3.26% | 183,581,331 | 82.74% | 39,732 |
18. 우선매수권부실허가(일반) | 175,982,388 | 95.86% | 7,602,205 | 4.14% | 183,584,593 | 82.74% | 36,470 |
19. 우선매수권(인수 또는 자본투자)의 취소 승인 | 168,246,123 | 91.85% | 14,920,062 | 8.15% | 183,166,185 | 82.55% | 454,878 |
20. 회사가 보통주를 매입할 수 있는 권한을 부여하기 위해 | 182,110,127 | 99.32% | 1,251,967 | 0.68% | 183,362,094 | 82.64% | 258,969 |
21. 회사가 14일 이상의 명확한 통지로 총회를 개최할 수 있는 권한을 부여합니다. | 178,012,603 | 96.95% | 5,601,835 | 3.05% | 183,614,438 | 82.75% | 6,625 |
22. To approve the Rule 9 Waiver (Buyback Waiver) | 72,087,355 | 56.62% | 55,225,852 | 43.38% | 127,313,207 | 57.38%3 | 277,747 |
23. To approve the Rule 9 Waiver (Existing Awards Waiver) | 119,728,008 | 94.04% | 7,583,303 | 5.96% | 127,311,311 | 57.38%3 | 279,643 |
24. To approve the Rule 9 Waiver (2024 Awards Waiver) | 119,728,008 | 94.04% | 7,583,303 | 5.96% | 127,311,311 | 57.38%3 | 279,643 |
25. To approve the Rule 9 Waiver (2025 Awards Waiver) | 119,727,713 | 94.04% | 7,583,598 | 5.96% | 127,311,311 | 57.38%3 | 279,643 |
1 Issued Ordinary Share capital of the Company (excluding treasury shares).
2 A "withheld" vote is not a vote in law and is not counted in the calculation of the proportion of votes "for" or "against" a resolution.
3 In order to comply with the City Code on Takeovers and Mergers, only the votes cast by the independent shareholders were counted for the purposes of Resolutions 22 to 25.
최종 배당 선언
The dividend of 47 cents per share will be paid on 3 May 2024 to shareholders on the register at the close of business on 22 March 2024. Shareholders who are not resident in Jordan have been given the option of receiving their dividend in Pounds Sterling. The exchange rate in respect of this dividend will be $1.265373 £1에. 요르단 디나르의 환율은 약 $1에서 0.708JD로 미국 달러로 고정되어 있습니다.
Resolution 22 - approval of the Rule 9 Waiver (Buyback Waiver)
Resolution 22, being the ordinary resolution to approve the waiver of Rule 9 of the City Code on Takeovers and Mergers (the 'Rule 9 Waiver (Buyback Waiver)'), in connection with any increase in the Darhold Concert Party's holdings in the Company's voting capital to 30% or more, resulting from the exercise of the Company's share buyback authority pursuant to Resolution 20, was duly passed by 56.62% of the votes cast by the independent shareholders of the Company (being holders of Ordinary Shares other than the Darhold Concert Party) with 43.38% of the votes against. Resolution 22 enables Hikma to fully exercise the authority granted under Resolution 20 to make on-market purchases of up to approximately 10% of its issued Ordinary Share capital, which is a standing authority sought by the Company on an annual basis and at today's AGM was approved with a majority of 99.32%. Resolutions 20 and 22 together provide the Company with additional flexibility to return value to shareholders, including through a possible future buyback programme. Had Resolution 22 not been passed, the Company's optionality in this regard would have been restricted. Hikma will continue to engage with proxy advisers and shareholders on the rationale and merits of the Rule 9 Waiver (Buyback Waiver) as part of a constructive dialogue.
- 끝 -
문의 :
Hikma 제약 PLC | |
헬렌 미들미스트 그룹 회사 비서 | +44 20 7399 2670 |
RNS는 귀하의 IP 주소를 사용하여 약관 준수 여부를 확인하고, 귀하가 이 커뮤니케이션에 포함된 정보를 사용하는 방식을 분석하고, 그러한 분석을 익명으로 다른 사람과 상용 서비스의 일부로 공유할 수 있습니다. RNS와 런던 증권 거래소가 귀하가 제공한 개인 데이터를 사용하는 방법에 대한 자세한 내용은 개인 정보 보호 정책을 참조하십시오.